Level 1 - Absolute Beginner

Some people take a medicine called Ozempic. It helps people lose weight. Now scientists think it may also help stop cancer.

Doctors studied more than 111,000 women. Women who took the medicine had less breast cancer. This is very interesting news.

The medicine is called a GLP-1 drug. Ozempic and Wegovy are both GLP-1 drugs. Women who took them had a 30 percent lower chance of getting breast cancer.

Scientists say they need more studies to be sure. But this is very good news. Many people are excited about this discovery.

medicine

a substance you take to treat or prevent illness

cancer

a serious illness where bad cells grow in the body

drug

a chemical substance used as a medicine

weight

how heavy something or someone is

study

careful research done to learn something new

risk

the chance that something bad will happen

scientist

a person who studies how the world works

discover

to find or learn something that was not known before

Level 2 - Elementary

Researchers at the University of Pennsylvania have found that women who take GLP-1 weight-loss drugs are about 30 percent less likely to develop breast cancer. The finding was published in June 2026 and presented at the American Society of Clinical Oncology annual meeting.

The study examined the health records of 111,646 women between the ages of 45 and 80. All of the women had a body mass index (BMI) of 25 or higher, which means they were overweight or obese. Those taking GLP-1 drugs like Ozempic and Wegovy had significantly lower rates of breast cancer.

In the full study group, women on GLP-1 drugs had 35.1 percent lower odds of developing breast cancer. In a more carefully matched comparison group, the reduction was 30.5 percent. These are large differences that scientists say deserve further investigation.

The study is observational, meaning doctors did not ask women to take the drugs for the research. They simply compared women who were already taking the drugs to those who were not. Because of this, scientists say a proper clinical trial is needed to confirm whether the drugs directly protect against cancer.

GLP-1

a type of hormone-based drug that helps control blood sugar and reduce appetite

observational study

research that watches what happens naturally, without changing what people do

BMI

body mass index, a measure of body fat based on height and weight

odds

the likelihood or probability of something happening

clinical trial

a carefully controlled study that tests whether a treatment actually works

obese

having a very high body weight that can harm health

oncology

the branch of medicine that studies and treats cancer

investigation

a careful search or study to learn more about something

Level 3 - Intermediate

A large observational study published on June 2, 2026, in JCO Oncology Practice has found that women taking GLP-1 receptor agonists, which include popular weight-loss medications such as semaglutide (Ozempic and Wegovy), may face approximately 30 percent lower odds of developing breast cancer. The research was simultaneously presented at the 2026 American Society of Clinical Oncology Annual Meeting, one of the world's most prominent cancer conferences.

The study team, led by researchers at the University of Pennsylvania Perelman School of Medicine, reviewed health records from 111,646 women aged 45 to 80 with a BMI of 25 or higher who had undergone breast imaging at Penn Medicine facilities between January 2022 and June 2025. In the full study population, women taking GLP-1 medications had 35.1 percent lower odds of a breast cancer diagnosis. In a carefully matched analysis comparing similar patients, the reduction held at 30.5 percent.

Scientists believe several mechanisms could explain the association. GLP-1 drugs are known to suppress appetite, reduce visceral fat, and lower insulin resistance, all of which are independently linked to lower breast cancer risk. Whether the protective effect stems from weight loss itself or from direct biological actions of GLP-1 molecules on breast tissue remains an open question.

Importantly, because this was an observational study and not a randomised controlled trial, researchers cannot definitively state that the drugs caused the cancer reduction. Confounding factors, such as overall health consciousness among patients choosing to take these medications, could partially explain the association. The findings have prompted the planning of a prospective clinical trial to investigate the relationship further.

receptor agonist

a molecule that binds to a cell receptor and activates it, mimicking a natural substance

semaglutide

the active ingredient in Ozempic and Wegovy, a GLP-1 receptor agonist

visceral fat

fat stored around the internal organs, linked to increased disease risk

insulin resistance

a condition in which cells do not respond normally to the hormone insulin

mechanism

the biological or chemical process by which something produces an effect

confounding factor

a variable that influences both the cause and the outcome in a study, complicating conclusions

prospective

looking forward in time; a prospective study follows people into the future

association

a statistical link between two things, which may or may not be cause-and-effect

Level 4 - Advanced

A landmark observational cohort study published in JCO Oncology Practice on June 2, 2026, and presented simultaneously at the 2026 American Society of Clinical Oncology Annual Meeting, has identified a striking 30 to 35 percent reduction in breast cancer incidence among women prescribed GLP-1 receptor agonists, chiefly semaglutide (marketed as Ozempic for glycaemic control and Wegovy for obesity management). The findings, from the University of Pennsylvania Perelman School of Medicine, are among the most compelling yet for a cancer-prevention role of this rapidly expanding drug class.

The retrospective analysis covered 111,646 women aged 45 to 80 with a BMI of 25 kg/m2 or higher who had undergone breast imaging at Penn Medicine facilities between January 2022 and June 2025. In the unadjusted full cohort, GLP-1 users demonstrated 35.1 percent lower odds of a breast cancer diagnosis (adjusted OR 0.649, 95% CI 0.561 to 0.751). In a 1:3 propensity-score-matched analysis controlling for comorbidities, imaging modality, hormone-receptor status, and prior cancer history, the association held at 30.5 percent reduced odds (matched OR 0.695, 95% CI 0.602 to 0.802).

The mechanistic plausibility is multifactorial. GLP-1 receptor agonists reduce visceral adiposity and circulating insulin, both established breast cancer risk factors, through suppression of hepatic gluconeogenesis and peripheral insulin resistance. Preclinical data also suggest direct GLP-1R signalling in breast epithelium may attenuate estrogen-driven proliferation and upregulate apoptotic pathways in HER2-negative cells, providing a weight-independent biological rationale. Whether the dominant protective pathway is hormonal, metabolic, or receptor-mediated remains an active research question.

The study's authors explicitly caution that an observational design precludes causal inference: unmeasured confounders such as overall health-seeking behaviour, dietary quality, physical activity, and concomitant use of statins or metformin could partially mediate the observed association. A prospective randomised controlled trial, likely requiring 4,000 to 6,000 participants followed over five to seven years, has been proposed to resolve the question. If confirmed, GLP-1 agents could represent the first widely available systemic cancer chemopreventive since tamoxifen, at a fraction of the side-effect burden.

cohort study

a research study that follows a group of people over time to observe outcomes

propensity-score matching

a statistical method that creates comparable groups in observational research to reduce bias

adiposity

the state of having excess body fat, particularly visceral fat around the organs

gluconeogenesis

the metabolic process by which the liver produces glucose from non-sugar sources

apoptotic

relating to the programmed, controlled death of cells that is essential for healthy tissue